Vertex Pharmaceuticals (VRTX) Gross Profit (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Gross Profit of $2.6 billion for Q1 2026, up 7.76% year-over-year from $2.4 billion in Q1 2025, and down 4.77% quarter-over-quarter from $2.7 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Gross Profit (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Gross Profit history runs 18 years deep, the most recent figure standing at $2.6 billion for Q1 2026.
- In Q1 2026, Gross Profit rose 7.76% year-over-year to $2.6 billion; the TTM figure through Mar 2026 stood at $10.5 billion (up 10.35% YoY), while the FY2025 annual figure was $10.4 billion, up 9.07% from the prior year.
- Gross Profit for Q1 2026 stood at $2.6 billion, down from $2.7 billion in the prior quarter.
- The five-year high for Gross Profit was $2.7 billion in Q4 2025, with the low at $1.9 billion in Q1 2022.
- The 5-year median for Gross Profit is $2.3 billion (2024), against an average of $2.3 billion.
- The sharpest annual moves came in 2022 and 2025: Gross Profit rose 23.57% in 2022, then grew 2.52% in 2025.
- Vertex Pharmaceuticals' Gross Profit stood at $2.0 billion in 2022, then rose by 6.45% to $2.1 billion in 2023, then climbed by 15.76% to $2.5 billion in 2024, then advanced by 9.46% to $2.7 billion in 2025, then dropped by 4.77% to $2.6 billion in 2026.
- Business Quant data shows VRTX's Gross Profit at $2.6 billion in Q1 2026, $2.7 billion in Q4 2025, and $2.7 billion in Q3 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|